Abbott Laboratories (ABT) is a Medical - Devices company in the Healthcare sector, currently trading at $101.07. It has a SharesGrow Score of 80/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ABT = $191.61 (+89.6% from the current price, the stock appears undervalued). Analyst consensus target is ABT = $138 (+36.2% upside).
Valuation: ABT trades at a trailing Price-to-Earnings (P/E) of 27.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.68.
Financials: revenue is $44.3B, +0.7%/yr average growth. Net income is $6.5B, growing at +21.8%/yr. Net profit margin is 14.7% (healthy). Gross margin is 55.5% (-0.6 pp trend).
Balance sheet: total debt is $15.1B against $52.1B equity (Debt-to-Equity (D/E) ratio 0.29, conservative). Current ratio is 1.58 (strong liquidity). Debt-to-assets is 17.4%. Total assets: $86.7B.
Analyst outlook: 30 / 40 analysts rate ABT as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 58/100 (Partial), Growth 73/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 86/100 (Pass), Future 85/100 (Pass), Income 55/100 (Partial).
